Expression of Stromal Caveolin- 1 May Be a Predictor for Aggressive Behaviour of Breast Cancer

Abstract

Caveolin-1 (Cav-1) is well known as a principal scaffolding protein of caveolae which are specialized plasma membrane structures. The role of Cav-1 in tumorigenesis of breast cancers is relatively less studied. The aim of the present study is to describe the biological roles of Cav-1 in breast cancers considering its contrasting dual functions as an oncogene and as a tumor suppressor. This study included 71 females with breast cancer who had been histopathologically diagnosed in Private Gunes Pathology Laboratory between the years 2007, and 2012. The mean age is 52.48 ± 12.8 years. Patients were followed up for a mean period of 47.97 ± 20.48 months. We didn't determine Cav-1 positive tumor cells. In 36 cases (50.7%), there were stromal expressions of Cav-1. In the statistical analysis, there was a statistically significant correlation between Cav-1 expression and ER (p = 0.033), metastasis (p = 0.005), lymphatic invasion (p = 0.000), nodal metastasis (p = 0,003), perinodal invasion (p = 0.003), metastasis (p = 0.005) and survival (p = 0.009). We found that Cav-1 expression is associated with tumor size, histological grade, lymph node involvement. Accordingly, we have suggested that Cav-1 may be a predictive biomarker for breast cancer.

Inhibition of FASN and ERα signalling during hyperglycaemia-induced matrix-specific EMT promotes breast cancer cell invasion via a caveolin-1-dependent mechanism

“…Silencing of caveolin-1 using siRNA blocked the ability of fulvestrant to induce the cell invasion that was accompanied by a reduction in SLUG mRNA levels. Caveolin-1 is highly expressed in invasive breast cancer cells consistent with reports linking caveolin-1 expression with tumour aggressiveness and poorer prognosis [ 44 , 45 ] and more recently caveolin-1 has been shown to play a role in EMT [ 17 , 18 ]. Given the emerging role of caveolin-1 in breast cancer progression, our findings raise the possibility of exploiting caveolin-1 as a therapeutic target to prevent invasion or as a clinical biomarker.…”

Caveolin‐1, cancer and therapy resistance

“…Again, these results showed that loss of CAV1 in gastric cancer alters the activation status of CAFs and thus may serve as a potential biomarker for gastric cancer . Further on, increased expression of epithelial CAV1 in advanced‐stage cancers was accompanied by a loss of stromal CAV1 in colon, breast, prostate, bladder, esophagus and thyroid cancers …”

“…123 Further on, increased expression of epithelial CAV1 in advanced-stage cancers was accompanied by a loss of stromal CAV1 in colon, breast, prostate, bladder, esophagus and thyroid cancers. 33,122,124,125 Conclusively, a characteristic shift in stromal-epithelial CAV1 in advanced and metastatic tumor stages with a loss of stromal CAV1 and an increase in expression of epithelial CAV1 highlights CAV1 as being a tissue and stage-specific tumor modulator ( Fig. 2).…”

Rafting Down the Metastatic Cascade: The Role of Lipid Rafts in Cancer Metastasis, Cell Death, and Clinical Outcomes

“…Overexpression of caveolin-1 in cancer associated fibroblasts (CAFs) correlated with increased low histological grade and favorable prognosis, while absent or depleted stromal caveolin-1 increased the risk of recurrence and predicted lymph node metastasis in early ductal carcinoma in situ (DCIS) (142,143). Additionally, high levels of epithelial caveolin-1 were correlated with more aggressive, triple negative breast cancer subtypes (144). These findings are supported by a study that examined subgroups of breast cancer patients with high tumoral caveolin-1 (T++) and weak stromal expression (S-).…”